Biotech

All Articles

Acelyrin drops izokibep, lays off 3rd of staff

.Regardless of izokibep keeping its newfound winning streak in the medical clinic, Acelyrin is actua...

Rivus' phase 2 obesity-related heart failure test reaches endpoint

.Rivus Pharmaceuticals has actually plumped up the leads of its own fat-busting, muscle-sparing drug...

Ovid halts preclinical work, IV course after soticlestat neglect

.Ovid Therapeutics already exposed last month that it was actually trimming its head count as the fi...

Eli Lilly opens $700M nucleic acid R&ampD center in Boston Seaport

.Eli Lilly has opened a $700 million R&ampD facility in the Boston Port, boosting its own RNA and al...

Boundless Bio creates 'modest' unemployments five months after $100M IPO

.Simply 5 months after protecting a $100 million IPO, Limitless Bio is already laying off some staff...

Halda's $126M will advance 'secure and eliminate' tumor drugs

.The first stages of oncology R&ampD may not be short of appealing brand new modalities, as well as ...

Lykos 'regrets' not revealing research violations with publisher

.Psychopharmacology has taken three posts concerning midstage clinical trial records determining Lyk...

Analysts dig into Avidity's DMD gain, exposing nuances in information

.Avidity Biosciences amazed entrepreneurs with phase 1/2 records in Duchenne muscular dystrophy (DMD...

Actinogen's cortisol blocker neglects phase 2 depression research

.Actinogen Medical's cortisol blocker has overlooked the main endpoint of a phase 2 study in depress...

Bivictrix determines going private only technique to take ADC right into clinic

.Antibody-drug conjugates (ADCs) have been at the center of lots of a billion-dollar biobuck licensi...